These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1343 related items for PubMed ID: 29463558

  • 1. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
    Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Clin Cancer Res; 2018 May 15; 24(10):2417-2429. PubMed ID: 29463558
    [Abstract] [Full Text] [Related]

  • 2. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis.
    Jiang L, Zhao Y, Liu F, Huang Y, Zhang Y, Yuan B, Cheng J, Yan P, Ni J, Jiang Y, Wu Q, Jiang X.
    Cell Commun Signal; 2024 Aug 07; 22(1):391. PubMed ID: 39113090
    [Abstract] [Full Text] [Related]

  • 3. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 4. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.
    Clin Cancer Res; 2018 Jan 01; 24(1):234-247. PubMed ID: 29074603
    [Abstract] [Full Text] [Related]

  • 5. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
    Ma S, Yang LL, Niu T, Cheng C, Zhong L, Zheng MW, Xiong Y, Li LL, Xiang R, Chen LJ, Zhou Q, Wei YQ, Yang SY.
    Sci Rep; 2015 Oct 26; 5():15646. PubMed ID: 26497577
    [Abstract] [Full Text] [Related]

  • 6. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, Nguyen B, Jung E, Aplan PD, Ghiaur G, Jones RJ, Small D.
    Blood; 2016 Jun 09; 127(23):2867-78. PubMed ID: 27103744
    [Abstract] [Full Text] [Related]

  • 7. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan 09; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y, Sun L, Xu Y, Fu L, Li Y, Bao X, Fu H, Xie C, Lou L.
    Cancer Lett; 2018 Apr 28; 420():49-59. PubMed ID: 29409989
    [Abstract] [Full Text] [Related]

  • 9. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 10. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.
    Li D, Li T, Shang Z, Zhao L, Xu Q, Tan J, Qin Y, Zhang Y, Cao Y, Wang N, Huang L, Zhu X, Zhou K, Chen L, Li C, Xie T, Yang Y, Wang J, Zhou J.
    Signal Transduct Target Ther; 2020 Mar 13; 5(1):21. PubMed ID: 32296014
    [Abstract] [Full Text] [Related]

  • 11. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
    Zhao MN, Su L, Song F, Wei ZF, Qin TX, Zhang YW, Li W, Gao SJ.
    Acta Haematol; 2024 Mar 13; 147(3):310-324. PubMed ID: 37926079
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.
    Clin Cancer Res; 2019 Nov 15; 25(22):6815-6826. PubMed ID: 31320594
    [Abstract] [Full Text] [Related]

  • 13. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.
    Blood; 2009 Jun 11; 113(24):6215-24. PubMed ID: 18955566
    [Abstract] [Full Text] [Related]

  • 14. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.
    Mol Cancer Ther; 2015 Oct 11; 14(10):2364-73. PubMed ID: 26206337
    [Abstract] [Full Text] [Related]

  • 15. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, Wang F, Naren D, Cui Y, Liu X, Qu Y, Luo H, Yang Y, Wei H, Guo Y.
    Biochem Pharmacol; 2021 Jun 11; 188():114538. PubMed ID: 33831397
    [Abstract] [Full Text] [Related]

  • 16. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.
    J Hematol Oncol; 2013 Mar 16; 6():21. PubMed ID: 23497456
    [Abstract] [Full Text] [Related]

  • 17. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H, Zeng D, Shen Z, Liao J, Wang X, Liu Y, Zhang X, Kong P.
    Oncotarget; 2016 Jun 28; 7(26):40387-40397. PubMed ID: 27248172
    [Abstract] [Full Text] [Related]

  • 18. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 19. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 23; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 20. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B, Zhao Y, Wang X, Gong P, Ge W.
    Leukemia; 2017 Apr 23; 31(4):913-921. PubMed ID: 27773927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.